Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 14/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21179705 | 0.84 | OPRL1 (0.74) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL23034688 | 0.84 | OPRL1 (0.53) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL20229892 | 0.84 | OPRL1 (0.74) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL23034686 | 0.84 | OPRL1 (0.53) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL21179603 | 0.83 | OPRL1 (0.53) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL23034791 | 0.80 | OPRM1 (0.40) | OPRL1OPRM1OPRD1OPRK1SLC18A3 | |
| SCHEMBL1786483 | 0.76 | KDM4E (0.52) | OPRL1OPRM1OPRD1KDM4EMEN1 | |
| SCHEMBL23034793 | 0.74 | OPRL1 (0.72) | OPRL1OPRM1OPRD1OPRK1TMEM97 | |
| SCHEMBL20229893 | 0.72 | OPRL1 (0.74) | OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL18920998 | 0.72 | OPRL1 (0.74) | OPRL1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10358432-B2 | Piperdinyl nociceptin receptor compounds | ASTRAEA THERAPEUTICS, LLC (US) | 2019-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10358432-B2 | Piperdinyl nociceptin receptor compounds | OPRL1, OPRK1, OPRD1 | OPRL1 1/4885OPRM1 4/4885OPRD1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.